High-density lipoproteins during sepsis: from bench to bedside
Open Access
- 7 April 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Critical Care
- Vol. 24 (1), 1-11
- https://doi.org/10.1186/s13054-020-02860-3
Abstract
High-density lipoproteins (HDLs) represent a family of particle characterized by the presence of apolipoprotein A-I (apoA-I) and by their ability to transport cholesterol from peripheral tissues back to the liver conferring them a cardioprotective function. HDLs also display pleiotropic properties including antioxidant, anti-apoptotic, anti-thrombotic, anti-inflammatory, or anti-infectious functions. Clinical data demonstrate that HDL cholesterol levels decrease rapidly during sepsis and that these low levels are correlated with morbi-mortality. Experimental studies emphasized notable structural and functional modifications of HDL particles in inflammatory states, including sepsis. Finally, HDL infusion in animal models of sepsis improved survival and provided a global endothelial protective effect. These clinical and experimental studies reinforce the potential of HDL therapy in human sepsis. In this review, we will detail the different effects of HDLs that may be relevant under inflammatory conditions and the lipoprotein changes during sepsis and we will discuss the potentiality of HDL therapy in sepsis.This publication has 109 references indexed in Scilit:
- Plasma HDL Reduces Nonesterified Fatty Acid Hydroperoxides Originating from Oxidized LDL: a Mechanism for Its Antioxidant AbilityLipids, 2013
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- Inflammation modulates human HDL composition and function in vivoAtherosclerosis, 2012
- High Density Lipoprotein (HDL) Promotes Glucose Uptake in Adipocytes and Glycogen Synthesis in Muscle CellsPLOS ONE, 2011
- Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and AtherosclerosisThe New England Journal of Medicine, 2011
- High-Density Lipoprotein Suppresses the Type I Interferon Response, a Family of Potent Antiviral Immunoregulators, in Macrophages Challenged With LipopolysaccharideCirculation, 2010
- The apolipoprotein A-I mimetic peptide 4F prevents defects in vascular function in endotoxemic ratsJournal of Lipid Research, 2010
- Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic β-Cell DysfunctionDiabetes Care, 2010
- Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJCI Insight, 2007